Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Trial Using Humira in Netherton Syndrome

Next Previous
Trial Profile

Phase II Clinical Trial Using Humira in Netherton Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Congenital ichthyosiform erythroderma
  • Focus Therapeutic Use
  • Acronyms AntiTNF-SN

    • Most Recent Events

    • 16 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 11 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
    • 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top